Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Bibliographic Details
Main Authors: Wellens, J, Edmans, M, Obolski, U, McGregor, CGC, Simmonds, P, Turner, M, Jarvis, L, Skelly, D, Dunachie, S, Barnes, E, Eyre, DW, Colombel, J-F, Wong, S-Y, Klenerman, P, Lindsay, JO, Satsangi, J, Thompson, CP
Format: Journal article
Language:English
Published: BMJ Publishing Group 2021

Similar Items